BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/15/2025 3:58:00 AM | Browse: 176 | Download: 581
 |
Received |
|
2024-08-11 16:47 |
|
Peer-Review Started |
|
2024-08-11 16:47 |
|
First Decision by Editorial Office Director |
|
2024-12-12 07:45 |
|
Return for Revision |
|
2024-12-12 07:45 |
|
Revised |
|
2024-12-22 02:57 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-12-30 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-12-30 08:50 |
|
Articles in Press |
|
2024-12-30 08:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-13 01:18 |
|
Publish the Manuscript Online |
|
2025-01-15 03:58 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xiao-Peng Fu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou 350122, Fujian Province, China. 1220105011@fjtcm.edu.cn |
| Key Words |
Sodium-glucose cotransporter 2 inhibitors; Hyperuricemia; Gout; Uric acid reduction; Chronic heart failure |
| Core Tip |
This article explores the dual benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in managing hyperuricemia and gout, particularly in patients with type 2 diabetes and cardiovascular complications. By highlighting the ability of SGLT2 inhibitors to lower uric acid levels and reduce the risk of gout flare-ups, this article provides insights into their potential as a comprehensive treatment option. The review also emphasizes the importance of understanding the underlying mechanisms, offering a new perspective on optimizing the clinical application of SGLT2 inhibitors in high-risk patients. |
| Publish Date |
2025-01-15 03:58 |
| Citation |
Fu XP. Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management. World J Clin Cases 2025; 13(14): 100262
|
| URL |
https://www.wjgnet.com/2307-8960/full/v13/i14/100262.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v13.i14.100262 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
